Proteinase 3 Antibodies, IgG
| Label Mnemonic: | PR3 |
| Epic code: | LAB1344 |
| Downtime form: | Doctor/Provider Orders - Pathology Core and Specialty Care Nursery |
Chemistry
6240 RCP
356-3527
6240 RCP
356-3527
Specimen(s):
Serum
Collection Medium:
 |
| Red top tube 5 mL (Clot Activator) |
Minimum:
Adult - 5 mL; red top tube
Pediatric - 2 mL; red top tube
Pediatric - 2 mL; red top tube
Testing Schedule:
24 hrs/day, 7 days a week, including holidays.
Turn Around
Time:
3 hours (upon receipt in laboratory)
Reference Range:
Negative: < 0.4 antibody index (AI)
Equivocal: 0.4-0.9 AI
Positive: 1.0 AI or greater
Equivocal: 0.4-0.9 AI
Positive: 1.0 AI or greater
Interpretive Data:
Proteinase 3 (PR3) antibodies are used for evaluating patients
suspected of having Wegener granulomatosis (WG). Tests for PR3
antibodies should be employed with clinical history, physical
examination, and other serologic tests in the initial diagnostic
evaluation of patients with clinical features of vasculitis. It is
recommended that initial workup of such patients include "Neutrophil
Cytoplas.Screen (ANCA)" (LAB1327). Proteinase 3 antibodies and
myeloperoxidase antibodies are performed if ANCA screen is positive or
inconclusive.
Titers to PR3 antibodies may be useful to follow treatment response.
Titers to PR3 antibodies may be useful to follow treatment response.
Comments:
Assay methodology and reference ranges changed February 5, 2013.
References:
Finkielman JD et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 2007; 643:e9- e14.
Russel KA et al. Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol 2002; 103:196- 203.
Savige J et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999; 111:507-513.
References:
Finkielman JD et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 2007; 643:e9- e14.
Russel KA et al. Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol 2002; 103:196- 203.
Savige J et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999; 111:507-513.
Methodology:
Multiplex flow immunoassay
CPT Code:
83520
See also:
Anti-Neutrophil Cytoplasmic (ANCA) Screen, Serum
Anti-Neutrophil Cytoplasmic (ANCA) Screen, Serum